Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05763940Not ApplicableActive Not Recruiting

Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals

Role: collaborator

NCT04676126Phase 4Withdrawn

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

Role: collaborator

NCT03946085Not ApplicableCompleted

Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)

Role: lead

All 3 trials loaded